

JAMES (JAY) BROPHY



Curriculum Vitae 2023-05-12

Professor of Medicine

Epidemiology, Biostatistics and Occupational Health

McGill University

Contact info:

Personal website [@brophyj](#) [brophyj](#) [brophyj](#) [brophyj](#)

Education

Degree	Institution	Department	Location
PhD	McGill University Faculty of Medicine	Epidemiology and Biostatistics	Montreal QC
FRCPC	Université de Montreal Faculte de Medecine	Cardiology	Montreal QC
MD	McMaster University Faculty of Health Sciences	Medicine	Hamilton ON
M.Eng	McMaster University Faculty of Engineering	Chemical engineering	Hamilton ON
B.Eng	McGill University Faculty of Engineering	Chemical engineering	Montreal QC

Awards

Award	Date
Fellow Canadian Academy of Health Sciences	Sept 2018
Fellow Canadian Cardiovascular Society	May 2017




Current Research Funding

Title	Agency	Date	Role
Appui à la recherche en évaluation des technologies et des pratiques de pointe dans les CHU (Health Technology and Evidence Based Medicine)	Fonds de Recherche Quebec Sante	July 2018-23	PI
Ticagrelor compared to clopidogrel in acute coronary syndromes - the TC4 comparative effectiveness study	Canadian Institutes of Health Research	April 2019-23	PI
Evaluating the Trajectory of Aortic Stenosis (AS) in Quebec patients - Diagnosis, Treatments, and Outcomes	Canadian Institutes of Health Research	Sept 2020 - 23	PI
The S. aureus Network Adaptive Platform Trial (SNAP) Canada: A Randomized Controlled Trial for Penicillin-susceptible, Methicillin-susceptible, and Methicillin resistant Staphylococcus aureus Bloodstream Infections in Hospitalized Patients	Canadian Institutes of Health Research	July 2021 - 2026	co-A
Comparative Effectiveness of Long-acting Insulins and Neutral Protamine Hagedorn (NPH) Insulin for the Prevention of Micro- and Macrovascular Complications Among Patients with Type 1 Diabetes	Canadian Institutes of Health Research	April 2023-2026	co-A

Publications

All publications (440 on 2023-05-12) as recorded in Google Scholar can be found [here](#) Citations 26709, h-index 61

Includes letters, editorials as well as original articles



JM Brophy, L Nadeau. Amiodarone vs dronedarone for atrial fibrillation: a retrospective cohort study. CJC open. 5 (1), 8-14. 2023.

L Azoulay, A St-Jean, M Dahl, J Quail, W Aibibula, JM Brophy, AW Chan, Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multi-site population-based cohort study. Journal of the American Academy of Dermatology. . 2023.

AA Rahman, J Michaud, S Dell'Aniello, EEM Moodie, JM Brophy, Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study. Neurology. 100 (12), e1309-e1320. 2023.

JM Brophy. Numbers don't lie—but tell only part of the story. CJC Open. . 2023.

JM Brophy. A Bayesian Perspective—Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest. medRxiv. 2023.02.13.23285890. 2023.

F Barili, JM Brophy, D Ronco, PO Myers, MS Uva, RMS Almeida, Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-analysis. JAMA Network Open. 6 (1), e2249321-e2249321. 2023.

TC Lee, S Murthy, O Del Corpo, J Senécal, G Butler-Laporte, ZN Sohani, Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. *Clinical Microbiology and Infection*. . 2022.

JM Brophy. Molnupiravir's authorisation was premature. *bmj*. 376. 2022.

AM Albuquerque, L Tramuja, LR Sewanan, DR Williams, JM Brophy. Mortality rates among hospitalized patients with COVID-19 infection treated with tocilizumab and corticosteroids: a Bayesian reanalysis of a previous meta-analysis. *JAMA Network Open*. 5 (2), e220548-e220548. 2022.

A Sharma, M Elharram, J Afilalo, A Flannery, M Afilalo, C Tselios, J Ni, A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. *American Heart Journal*. 247, 76-89. 2022.

M Gaudino, JM Brophy. The controversy on the treatment of left main coronary artery disease. *The Journal of Thoracic and Cardiovascular Surgery*. 163 (5), 1864-1869. 2022.

AM Albuquerque, I Eckert, L Tramuja, G Butler-Laporte, EG McDonald, Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. *Clinical Microbiology and Infection*. . 2022.

A Razaghi, E Oulouian, VK Randhawa, JP Ferreira, JM Brophy, Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*. 11 (10), e024833. 2022.

J Rouette, EG McDonald, T Schuster, JM Brophy, L Azoulay. Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. *BMJ open*. 12 (6), e057510. 2022.

TC Lee, S Murthy, O Del Corpo, J Senécal, G Butler-Laporte, ZN Sohani, Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis. *medRxiv*. 2022.01. 22.22269545. 2022.

S Perreault, A Dragomir, R Cote, A Lenglet, S De Denus, M Dorais, Comparative effectiveness and safety of low-dose oral anticoagulants in patients with atrial fibrillation. *Frontiers in pharmacology*. 12, 4099. 2022.

M Samuel, JM Brophy. Diabetes and atrial fibrillation: does the type of diabetes matter?. *European Journal of Preventive Cardiology*. . 2022.

J Rouette, EG McDonald, T Schuster, JM Brophy, L Azoulay. Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer A Population-Based Cohort Study. *Journal of the American Heart Association*. 11 (24), e026789. 2022.

JM Brophy. RE: Covid testing in travellers-can we be smarter?. . . 2022.

J Brophy. In the general population, salt substitutes vs. regular salt reduce BP levels, CV outcomes, and mortality. *Annals of Internal Medicine*. 175 (12), JC139. 2022.

JM Brophy. Understanding Associations, Social Inequities, and Cardiovascular Risks. *Canadian Journal of Cardiology*. 38 (12), 1918-1920. 2022.

X Xie, C Li, S Tiggelaar, F Simbulan, L Falk, JM Brophy. Developing a cross-validation tool for evaluating economic evidence in rapid literature reviews. *Journal of Comparative Effectiveness Research*. 11 (16), 1151-1160. 2022.

JM Brophy. Big Data, Big Expectations, and Big Judgements. *Canadian Journal of Cardiology*. 38 (10), 1567-1569. 2022.

A Rahman, J Michaud, S Dell'Aniello, E Moodie, JM Brophy, M Durand, Association between oral anticoagulants and risk of dementia in patients with non-valvular atrial fibrillation. *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY*. 31, 631-631. 2022.

J Rouette, E McDonald, T Schuster, I Matok, J Brophy, L Azoulay. Thiazide diuretics and risk of colorectal cancer. *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY*. 31, 69-70. 2022.

JM Brophy. In HF, SGLT2 inhibitors reduce HF hospitalizations at up to 2 y. *Annals of Internal Medicine*. 175 (8), JC87. 2022.

JM Brophy. mRNA COVID-19 vaccines were linked to myocarditis at 28 d (0.15 to 10 excess events/100 000 vaccinated persons). *Annals of Internal Medicine*. 175 (8), JC94. 2022.

AM Albuquerque, JM Brophy. Pacemaker risk following transcatheter aortic valve replacement-A Bayesian reanalysis. *International Journal of Cardiology*. 355, 32-36. 2022.

JM Brophy. After DES implantation, DAPT for 1 y vs.≤ 6 mo increased major bleeding in patients with high baseline bleeding risk. *Annals of Internal Medicine*. 175 (4), JC45. 2022.

J Brophy. Molnupiravir's authorisation was premature Regulatory decisions fall short of the wise stewardship required during a pandemic. *BMJ-BRITISH MEDICAL JOURNAL*. 376. 2022.

AM Albuquerque, I Eckert, L Tramuja, EG McDonald, G Butler-Laporte, Analysis plan: Version 1.1 Effect of Tocilizumab, Sarilumab, and Baricitinib on Mortality Among Patients Hospitalized for COVID-19: A Systematic Review and Meta-Regression. . . 2022.

JM Brophy. SARS-CoV-2 testing in travellers: Can we be smarter?. *CMAJ*. 194 (1), E20-E20. 2022.

M Etminan, JM Brophy, G Collins, M Nazemipour, MA Mansournia. To adjust or not to adjust: the role of different covariates in cardiovascular observational studies. *American Heart Journal*. 237, 62-67. 2021.

TC Lee, EG McDonald, G Butler-Laporte, LB Harrison, MP Cheng, Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. *International Journal of Infectious Diseases*. 104, 671-676. 2021.

SA Kutcher, JM Brophy, HR Banack, JS Kaufman, M Samuel. Emulating a randomised controlled trial with observational data: an introduction to the target trial framework. *Canadian Journal of Cardiology*. 37 (9), 1365-1377. 2021.

AM Albuquerque, L Tramujas, LR Sewanan, JM Brophy. Tocilizumab in COVID-19—A Bayesian reanalysis of RECOVERY. medRxiv. 2021.06.15.21258966. 2021.

M Aflaki, A Flannery, JP Ferreira, MP Cheng, N Kronfli, A Marelli, Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID-19 *Trials*. 22 (1), 1-3. 2021.

S Rinfret, I Jahan, K McKenzie, N Dendukuri, KR Baaney, S Mansour, The COVID-19 pandemic and coronary angiography for ST-elevation myocardial infarction, use of mechanical support, and mechanical complications in Canada: a Canadian Association *CJC open*. 3 (9), 1125-1131. 2021.

TJC Perreault S, Dragomir A, Côté R, Lenglet A, White-Guay B, de Denus S Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. *Pharmacotherapy*. . 2021.

JM Brophy. Bayesian analyses of cardiovascular trials—bringing added value to the table. *Canadian Journal of Cardiology*. 37 (9), 1415-1427. 2021.

M Samuel, JM Brophy, L D'Aronco, JC Tardif, P Khairy. Distorting effect of immortal time bias on the association between catheter ablation for atrial fibrillation and incident stroke: caveat emptor. *Canadian Journal of Cardiology*. 37 (3), 377-381. 2021.

JM Brophy. Key Issues in the Statistical Interpretation of Randomized Clinical Trials. *Canadian Journal of Cardiology*. 37 (9), 1312-1321. 2021.

G Nakhlé, JM Brophy, C Renoux, P Khairy, P Bélisle, J LeLorier. Domperidone increases harmful cardiac events in Parkinson's disease: A Bayesian re-analysis of an observational study. *Journal of Clinical Epidemiology*. 140, 93-100. 2021.

J Rouette, JM Brophy, T Schuster, L Azoulay. Treatment trajectory of antihypertensive drugs in UK primary care practices. *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY*. 30, 373-373. 2021.

AM Albuquerque, TC Lee, DR Williams, L Tramujas, JM Brophy. Analysis plan Does Sarilumab Reduce Mortality in Hospitalized Patients for COVID-19? A Bayesian Reanalysis. . . 2021.

Top citations (excluding guideline, multicentre RCTs)

MN Babapulle, L Joseph, P Bélisle, JM Brophy, MJ Eisenberg. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. *The Lancet*. 364 (9434), 583-591. 2004. cites = 916

JM Brophy, L Joseph, JL Rouleau. β -Blockers in congestive heart failure: a Bayesian meta-analysis. *Annals of internal medicine*. 134 (7), 550-560. 2001. cites = 603

M Sousa-Uva, FJ Neumann, A Ahlsson, F Alfonso, AP Banning, 2018 ESC/EACTS Guidelines on myocardial revascularization. *European Journal of Cardio-Thoracic Surgery*. 55 (1), 4-90. 2019. cites = 551

M Bally, N Dendukuri, B Rich, L Nadeau, A Helin-Salmivaara, E Garbe, Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. *bmj*. 357. 2017. cites = 502

I Shrier, JF Boivin, RJ Steele, RW Platt, A Furlan, R Kakuma, J Brophy, Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. *American journal of epidemiology*. 166 (10), 1203-1209. 2007. cites = 483